Ryan Specialty (RYAN) Financials

Ryan Specialty’s latest results show continued revenue growth and strong operating cash generation, but profitability has softened and leverage remains a key concern. The company reported Q2 2026 revenue of $916.6 million, up 7.2% from $855.2 million in Q2 2025 and 32.3% from Q2 2024. However, growth has moderated from the double-digit increases recorded in prior periods.

Operating income increased to $180.3 million from $95.5 million in Q1 2026, but declined 5.6% year over year from $191.1 million. As a result, the operating margin fell to approximately 19.7% in Q2 2026, compared with 22.3% in Q2 2025 and 23.6% in Q2 2024. Common shareholders received $42.3 million of net income, or $0.34 per diluted share, down from $52.0 million and $0.41 per share a year earlier.

Cash generation remains a relative strength. Operating cash flow was $293.0 million in Q2 2026, reversing the $167.4 million outflow recorded in Q1 and representing approximately 69% of consolidated net income. The improvement was helped by an $82.3 million contribution from changes in operating assets and liabilities, although working-capital movements have been highly volatile from quarter to quarter.

• Revenue continues to expand: Q2 revenue reached $916.6 million, more than double the $412.0 million reported in Q3 2022, although the pace of growth has slowed recently.
• Operating cash flow remains substantial: Ryan Specialty generated $293.0 million in operating cash flow in Q2 2026 after a $167.4 million outflow in Q1.
• Cash flow comfortably funded capital spending: Q2 operating cash flow covered $18.7 million of capital expenditures, leaving significant cash available for debt service, dividends and share repurchases.
• Share repurchases are supporting per-share results: The company repurchased $260.2 million of common equity in Q2 2026, and basic weighted-average shares declined to 125.3 million from 129.4 million in Q1.
• Quarterly profitability rebounded sequentially: Net income attributable to common shareholders rose to $42.3 million in Q2 from $17.6 million in Q1, while diluted EPS increased from $0.13 to $0.33.
• Working capital is a major swing factor: Changes in operating assets and liabilities contributed $82.3 million of cash in Q2 2026 but consumed $305.4 million in Q1, making quarterly cash flow less predictable.
• Acquisition-driven assets dominate the balance sheet: Goodwill and intangible assets totaled approximately $4.72 billion in Q2 2026, or about 39% of total assets. This reflects the company’s acquisition strategy but increases exposure to impairment and amortization charges.
• Operating margins have deteriorated: The Q2 2026 operating margin was approximately 19.7%, below the 22.3% reported in Q2 2025 and the 23.6% reported in Q2 2024.
• Common earnings declined year over year: Net income attributable to common shareholders fell 18.6% from Q2 2025, while diluted EPS dropped from $0.41 to $0.33.
• Leverage has increased: Short- and long-term debt totaled approximately $3.64 billion at June 30, 2026, up from $3.48 billion a year earlier and far above the roughly $1.97 billion reported in Q2 2024.

The balance sheet also warrants attention. Cash and equivalents declined to $140.1 million from $172.6 million a year earlier and $154.7 million at the end of Q1 2026. Total liabilities reached $10.95 billion, leaving common equity of only $509.4 million; much of the reported equity is represented by noncontrolling interests rather than common shareholders’ equity.

Overall, Ryan Specialty retains attractive growth and cash-generation characteristics, but investors should monitor whether revenue growth reaccelerates, margins stabilize and debt declines. The combination of elevated leverage, significant acquisition-related goodwill and intangible assets, and a large allocation of earnings to noncontrolling interests limits the benefit of consolidated profitability for common shareholders.